BBS-Bioactive Bone Substitutes Plc, Company announcement, 17 August 2023 at 12:00 p.m.
Conversion of convertible notes pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and Riverfort Global Opportunities PCC Ltd
BBS-Bioactive Bone Substitutes Plc (“BBS” or the “Company”) has received a request by Riverfort Global Opportunities PCC Ltd to convert a proportion of EUR 50,000 of the convertible notes into Company shares at a conversion price of EUR 0.39483 per share.
The Conversion price according to the terms and conditions is “90% of the lowest volume weighted average price of a trading day during ten trading days before the applicable subscription notice“.
The conversion shall be executed by transferring a total of 126,636 of treasury shares to Riverfort Global Opportunities PCC Ltd. After the transfer, the Company will hold a total of 101,451 treasury shares in its possession.
For more information, please contact:
Ilkka Kangasniemi, CEO,
+358 40 7080307,
ilkka.kangasniemi@bbs-artebone.fi
Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se
BBS in brief
BBS-Bioactive Bone Substitutes Plc is a orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our developed product, ARTEBONE®, is in the final stages of product development, and we are seeking the CE marking to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company’s headquarters are in Oulu, and we employ 20 people.
BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.
More information: www.bbs-artebone.fi
GE HealthCare is helping advance clinical and operational excellence in theranostics and molecular imaging through…
RLT_Angels Photo RLT Angels Association Further founding members include the European Association of Nuclear Medicine…
From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major…
Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined companyCRANFORD,…
Higher dose of Wegovy® provided average weight loss of 21% in people with obesity –…
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
